Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 7Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Prostate Adenocarcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Congenital Abnormalities 1Colorectal Neoplasms 1

Interventions

Paclitaxel 42Carboplatin 35pembrolizumab 25Surveys and Questionnaires 23Letrozole 15Radiotherapy 14Megestrol Acetate 14Blood Specimen Collection 14Bevacizumab 13olaparib 12Metformin 12dostarlimab 10Indocyanine Green 10durvalumab 9Observation 9Medroxyprogesterone Acetate 9Cisplatin 9lenvatinib 8atezolizumab 8Early Intervention, Educational 8Counseling 8niraparib 7Sentinel Lymph Node Biopsy 7Radiation 7Methods 7Magnetic Resonance Spectroscopy 7Lymph Node Excision 7Hysterectomy 7Everolimus 7abemaciclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Endometrial Neoplasms × entinostat × Clear all
NCT03924245 2022-04-04

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Vanderbilt-Ingram Cancer Center

Phase 1 Terminated
3 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡